Twist Bioscience vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Twist Bioscience Corp (TWST)

Q3 202619 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.

July 202619 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.

Latest19 Jun – 19 Aug 2026

▲4

Twist's AI-driven DNA demand and raised guidance fuel strong gains

AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.